弥漫大B细胞淋巴瘤中miR-339-5 p的表达及意义

目的：检测miR-339-5p在弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)中的表达,探讨miR-339-5p表达与DLBCL临床病理特征的关系。方法采用显色原位杂交技术检测123例 DLBCL 和20例淋巴结反应性增生( reactive lymphoid hyperplasia, RH)组织中miR-339-5p的表达,并采用免疫组化EnVision两步法检测DLBCL组织中Ki-67和BCL-6蛋白的表达,分析miR-339-5p与BCL-6表达的相关性及二者表达与DLBCL临床病理特征的关系。结果 DLBCL组织中miR-339-5p的阳性率(39．8%,49/123)显著低于RH组织(90．0%,18/20)。活化的B细胞型(ABC型)DLBCL组织中miR-339-5p阳性率(31．0%,22/71)明显低于生发中心的次级B细胞型(GCB型)(51．9%,27/52)。 miR-339-5p在DLBCL中表达降低与Ann Arbor分期晚以及国际预后指数IPI评分高有关(P均<0．05)。 ABC型、GCB型DLBCL中miR-339-5p阴性患者生存率均明显低于miR-339-5p阳性患者(P均<0．01)。 DLBCL中miR-339-5p与BCL-6蛋白表达呈显著负相关(P<0．01)。结论miR-339-5p低表达可能与DLBCL进展和预后不良相关。     

The unexpected evolution of a case of diffuse large B-cell non-Hodgkin lymphoma

The diffuse large B-cell lymphoma (DLBCL) represents the most common type of aggressive non-Hodgkin's lymphoma with a heterogeneous morphology, biology and clinical presentation. Gene expression profiling studies identified three distinct molecular subtypes of DLCBL arisen from B-cells at different stages of differentiation: germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, primary mediastinal B-cell lymphoma (PMBL). The most relevant oncogenic pathways in diffuse large B-cell lymphoma are: deregulated B-cell receptor/proliferation signaling, BCL6 and NF-kB constitutive expression, defects in apoptosis and neoangiogenesis. The treatment of DLBCL has been completely modified in the last ten years by combination of anti-CD20 monoclonal antibody (rituximab) and CHOP chemotherapy, which is now the first line therapy. In the last years, there have been reported several cases of progressive multifocal leukoencephalopathy (PML) at patients with rheumatoid arthritis treated with rituximab. Progressive multifocal leukoencephalopathy is possible as an adverse reaction to rituximab at patients treated with R-CHOP for diffuse large B-cell lymphoma.     

CD56阳性弥漫性大B细胞淋巴瘤一例

患者男,35岁.2007年3月因颈部肿胀,CT提示胸腺占位考虑恶性淋巴瘤压迫上腔静脉在外院治疗.术前化疗2个周期后行胸腺部位肿瘤切除,术后病理诊断:纵隔肿瘤化疗后大片坏死,残留极少量变性肿瘤组织.手术后又进行瘤床放疗,治疗结束B超及CT检查均未见明显异常.同年9月患者出现腰背部疼痛,CT检查发现后腹膜多发淋巴结肿大,于2007年10月来本院治疗.根据病史考虑纵隔肿瘤术后、放化疗后,后腹膜淋巴结受累,行姑息性放化疗.4个疗程治疗结束后肿瘤明显缩小.2008年3月患者于后腹膜胰头上方出现结节灶(3.4 cm×3.0 cm×3.0 cm),经治疗后无明显改变;同期左下颈部发现直径3.0 cm大小肿块,至2008年9月左颈肿块达6 cm×5 cm×5 cm,行左颈部肿块切取活检.     

子宫体原发弥漫性大B细胞淋巴瘤一例

患者女,78岁.绝经30余年,近1个月无明显诱因出现下腹部坠胀感,于2010年7月收入院.无明显腹痛,无阴道流血.妇科检查:老年性外阴,阴道通畅,宫颈光滑,下腹部可触及一个肿块,大小约7 cm×8 cm,无压痛,因患者肥胖附件触诊不清.肝脾未见异常,全身淋巴结无肿大.下腹部CT:盆腔肿块.下腹部磁共振检查:子宫底部肿瘤,考虑肉瘤可能.胸部X线片未见异常.外周血、骨髓涂片均正常.患者入院后行广泛全子宫、双附件切除术及盆腔淋巴结清扫术.     

弥漫大B细胞淋巴瘤中miR-5585-3p的表达及其意义

目的探讨miR-5585-3p在弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达与临床病理特征的相关性及其预后意义。方法选取12例DLBCL石蜡标本进行基因芯片扫描,依据fold change≥1.5、P≤0.05筛选出差异性表达的miRNAs,miR-5585-3p是其中之一。采用qRT-PCR检测95例DLBCL石蜡标本中miR-5585-3p的表达,15例淋巴结反应性增生组织作为对照,并结合患者临床病理学资料进行分析。结果 miR-5585-3p在DLBCL中的表达量显著高于淋巴结反应性增生组织(P0.001),且non-GCB亚型miR-5585-3p的表达水平是GCB型的2.4倍(P=0.006)。miR-5585-3p高表达与淋巴瘤国际预后指数(IPI)呈正相关(P=0.005)。Kaplan-Meier生存分析显示:DLBCL中高表达miR-5585-3p的患者生存率明显低于miR-5585-3p低表达者(P=0.049)。预后多因素Cox分析显示,年龄60岁(P=0.010)、IPI评分3~5分(P=0.004)、高表达miR-5585-3p(P=0.014)为DLBCL独立不良预后指标。结论 miR-5585-3p高表达可能与DLBCL不良预后有关。     

阑尾原发弥漫性大B细胞淋巴瘤一例

患者男,59岁.无明显诱因右下腹持续性疼痛半天,阵发性加剧,无放射痛,有恶心,无呕吐于2008年1月17日入院.体检:右下腹压痛、反跳痛明显,全身体表未触及肿大淋巴结,血常规检查:白细胞9.2×109/L,中性粒细胞84.5%,血红蛋白141 g/L,B超示:左肾多发性囊肿,阑尾肿胀明显.     

Clear cell variant of diffuse large B-cell lymphoma: a case report and review of the literature

Diffuse large B cell lymphoma (DLBCL) is a diffuse proliferation of large neoplastic B lymphoid cells with nuclear size equal to or exceeding that of normal macrophage nuclei. The DLBCL morphological variants are centroblastic, immunoblastic, T-cell- and histiocyte-rich, anaplastic, plasmablastic, anaplastic lymphoma kinase-positive, and primary mediastinal large B-cell lymphoma (PMBCL). These histopathologically-recognized morphological variants respond differently to treatment and have distinct prognoses. We report a case of a 43-year-old patient who presented pain in the lower abdomen that had begun four months prior. Ultrasound-guided biopsy revealed epithelial cell features and a partial alveolar growth pattern. We discovered large diffuse areas comprising large cells with slightly irregular nuclei and very clear cytoplasm. These features were similar to those of clear cell carcinoma in renal tissue, suggesting the possibility of an epithelial neoplasm. To test this possibility, immunohistochemistry for cluster designation markers was performed, but the diffuse areas were found to be positive only for CD45. Additional immunohistochemistry was performed, and the diffuse areas were found to be positive for CD20, CD79a, P53, and Mum-1. Based on these characteristics, a diagnosis of a clear cell variant of DLBCL was made, and the patient was treated with chemotherapy. Precise histological diagnosis is crucial for clinical management and ultimately for patient survival. There has been one additional report of a case of clear cell DLBCL, in outside the mediastinum. The features we identified can be used to define a new subtype of DLBCL. The expression of P53 and Mum-1 suggest a poor prognosis.     

结内外弥漫性大B细胞淋巴瘤的免疫表型和分化特征及预后的比较

目的探讨弥漫性大B细胞淋巴瘤（DLBCL）的临床生物学特征和预后并比较结内与结外的差异。方法分析142例DLBCL的临床病理资料,结内90例,结外52例（胃肠30例,其他22例）,并随访2～108个月,制备组织芯片,并经免疫组织化学EnVision法染色,观察CD10、bcl-6、MUM1蛋白的表达并进一步区分其生发中心B细胞（GCB细胞）和非生发中心B细胞的分化特征。结果胃肠道DLBCL常为Ⅰ～Ⅱ期,国际预后指标评分低,预后也好于结内及其他结外DLBCL。单个抗原的表达率,CD10为19％（27例）,bcl-6为51％（72例）,MUM1为58％（82例）。36％（51例）的DLBCL显示GCB细胞分化特征,64％（91例）的DLBCL显示非GCB细胞分化特征。结外DLBCL的bcl-6的表达（63％）高于结内DLBCL（43％）。在不同的结外部位,甲状腺等部位多见为GCB细胞分化的DLBCL;睾丸等部位多见为非GCB细胞分化的DLBCL。结论DLBCL显示生发中心B细胞和非生发中心B细胞分化特征,结内外以及结外不同部位的DLBCL有着不同的生物学特征和预后。     

老年鼻咽EB病毒阳性弥漫性大B细胞淋巴瘤一例

患者女,62岁.因发现"左颈肿物一个月"于2005年2月21日来我院就诊.鼻咽镜检查示:鼻咽明显狭窄,顶后壁及双侧壁见隆起型肿物.体检:双颈部多发淋巴结肿大,直径1.5 cm至3.0 cm不等.临床诊断:鼻咽癌待排除.     

miR-30b促进弥漫性大B细胞淋巴瘤细胞凋亡

目的 研究miR-30b通过调控脆性组氨酸三联体(FHIT)对于弥漫性大B细胞淋巴瘤(DLBCL)细胞活性的作用机制.方法 选取上海市闵行区肿瘤医院(2017年2月至2019年6月)DLBCL患者的肿瘤石蜡标本与同期淋巴结增生的石蜡标本分为DLBCL组与对照组;将DLBCL细胞分为WW组(DLBCL无转染组)、WZ组(...     

Pyothorax-associated lymphoma: a case showing transition from T-cell-rich polymorphic lesion to diffuse large B-cell lymphoma

Pyothorax-associated lymphoma was found in a man who had a history of collapse therapy for pulmonary tuberculosis about 50 years ago. An autopsy specimen revealed histology of diffuse large B-cell lymphoma with latency III Epstein-Barr virus (EBV) infection. However, an open biopsy 2 years and 7 months before death showed a polymorphic appearance with abundant T-lymphocytes. Most of the EBV-infected atypical lymphocytes did not express either B- or T-cell markers as far as examined in the paraffin-embedded biopsy specimen, and rearrangements of immunoglobulin and T-cell receptors were not found. It seemed difficult to diagnose a B-cell lymphoma at the time of biopsy. However, retrospectively considered, if a phenotype of EBV-infected atypical lymphocytes is uncertain in cases showing polymorphic appearance, it might be better to consider the future evolution to overt B-cell lymphoma. Since pyothorax-associated lymphoma shows latency III infection of EBV, at least the immunohistochemistry of EBNA-2 and LMP-1 seems helpful for the diagnosis to prove which cells are infected by EBV.     

Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma

Primary CNS diffuse large B-cell lymphoma (CNS DLBCL) is confined to the CNS, and constitutes a distinct entity. In the present study a series of 40 Japanese patients with CNS DLBCL who presented with neurological, but not systemic symptoms, was reviewed. Median survival was 18.7 months. CD5, CD10, Bcl-6, MUM-1, and Bcl-2 were positive in 30%, 10%, 84%, 100%, and 93% of patients, respectively. All CD10-negative patients had non-germinal center B-cell type. There was no significant difference in survival among the immunophenotypic subgroups. CNS DLBCL appeared to be homogenous as a group, which prompted the comparison with another distinct extranodal entity, intravascular large B-cell lymphoma (IVLBCL) in Japanese patients. CNS DLBCL patients did not differ in age, sex, or immunophenotype, including CD5 positivity, from IVLBCL patients, but were significantly less likely to have poor prognostic parameters than IVLBCL patients: the international prognostic index score was low or low–intermediate in 86% of CNS DLBCL patients and high or high–intermediate in 98% of IVLBCL patients. Notably, despite this difference, their survival curves almost overlapped. The present study highlights the issue of clinical distinctiveness of aggressive extranodal lymphomas, the peculiar migration and localization of which should be further clarified.     

原发皮肤弥漫性大B细胞淋巴瘤(腿型)一例

患者男,60岁.因右小腿皮肤结节2个月于2006年3月21日入院.患者于2005年11月发现右小腿皮肤有斑片状色素沉着,2006年1月右小腿出现红色斑疹及结节,进行性增大,高出皮面.     

Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course

Recent data from studies of experimental murine tumors and certain human tumors (primarily melanoma) suggest that tumor-infiltrating T-lymphocytes (T-cell TILs) represent a highly potent and specific host antitumor response. We conducted an immunohistochemical analysis of the T-cell TIL subpopulations in frozen tissue sections taken from 82 consecutive B-cell diffuse large cell lymphoma (DLCL) patients. Initially, we analyzed the relationship in these patients between relapse-free survival (RFS) and their T-cell TIL characteristics. Nineteen patients had a low percentage (less than 6% of Leu-2+ (suppressor/cytotoxic) T-cell TILs, and 63 patients had a high percentage (greater than 6%) of Leu-2+ TILs. We found that a low percentage of Leu-2+ TILs correlated with a reduction in RFS: at 20 mo follow-up, all 19 low Leu-2+ patients had relapsed, whereas 70% of the 63 high Leu-2+ patients remained relapse-free (P = 0.008). No significant correlations appeared between patients' T-cell TIL subsets and overall survival. The percentage of newly diagnosed tumors with low counts of Leu-4+ (pan-T) TILs was marginally greater among interleukin-2 (IL-2) receptor-positive tumors than among IL-2 receptor-negative tumors (50 versus 28%, P = 0.098), which suggests that specific phenotypic characteristics of B-cell DLCL may modulate the host T-cell TIL response. Our results indicate that the host's T-cell TIL response in B-cell DLCL can be quantitated from frozen tissue sections and that this response may be related to disease course. Further related TIL studies may lead to new immunorestorative therapeutic approaches for patients with deficient or aberrant cytotoxic T-lymphocyte host responses.     

原发皮肤弥漫性大B细胞淋巴瘤(腿型)一例

患者男,60岁.因右小腿皮肤结节2个月于2006年3月21日入院.患者于2005年11月发现右小腿皮肤有斑片状色素沉着,2006年1月右小腿出现红色斑疹及结节,进行性增大,高出皮面.